Ser548
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser548  -  MTA2 (human)

Site Information
PINRNQLsQNrGLGG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 18012470
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 )
Disease tissue studied:
cervical cancer ( 18 ) , cervical adenocarcinoma ( 18 ) , leukemia ( 14 ) , acute myelogenous leukemia ( 14 ) , lung cancer ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , non-small cell lung cancer ( 4 , 5 , 6 , 8 , 9 , 10 , 13 ) , non-small cell lung adenocarcinoma ( 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , non-small cell large cell lung carcinoma ( 5 , 8 ) , non-small cell squamous cell lung carcinoma ( 7 ) , small-cell lung cancer ( 2 , 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 17 ) , A549 (pulmonary) ( 4 ) , Cal-12T (pulmonary) ( 10 ) , Calu-3 (pulmonary) ( 6 ) , DMS153 (pulmonary) ( 9 ) , DMS53 (pulmonary) ( 3 ) , DMS79 (pulmonary) ( 2 ) , HCC15 (pulmonary) ( 7 ) , HCC44 (pulmonary) ( 10 ) , HCC78 (pulmonary) ( 8 ) , HCC827 (pulmonary) ( 6 ) , HeLa (cervical) ( 1 , 16 ) , HeLa S3 (cervical) ( 18 ) , HUES-9 ('stem, embryonic') ( 15 ) , K562 (erythroid) ( 12 ) , KG-1 (myeloid) ( 14 ) , LOU-NH91 (squamous) ( 7 ) , lung ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , NCI-H128 (pulmonary) ( 2 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1355 (pulmonary) ( 4 ) , NCI-H1417 (pulmonary) ( 2 ) , NCI-H1437 (pulmonary) ( 9 , 10 ) , NCI-H1650 (pulmonary) ( 6 ) , NCI-H1666 (pulmonary) ( 10 ) , NCI-H1703 (squamous) ( 7 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1781 (pulmonary) ( 8 ) , NCI-H1792 (pulmonary) ( 4 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H1975 (pulmonary) ( 6 ) , NCI-H2073 (pulmonary) ( 7 , 9 ) , NCI-H209 (pulmonary) ( 2 , 9 ) , NCI-H2106 (pulmonary) ( 6 ) , NCI-H2228 (pulmonary) ( 8 ) , NCI-H23 (pulmonary) ( 4 ) , NCI-H2342 (pulmonary) ( 7 ) , NCI-H2405 (pulmonary) ( 10 ) , NCI-H3122 (pulmonary) ( 8 ) , NCI-H3255 (pulmonary) ( 13 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H441 (pulmonary) ( 4 ) , NCI-H446 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 5 ) , NCI-H524 (pulmonary) ( 2 ) , NCI-H526 (pulmonary) ( 3 ) , NCI-H661 (pulmonary) ( 8 ) , NCI-H69 (pulmonary) ( 3 ) , NCI-H82 (pulmonary) ( 3 ) , NCI-H838 (pulmonary) ( 9 )

Upstream Regulation
Treatments:
angiotensin_2 ( 17 ) , nocodazole ( 18 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

12

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

13

Rikova K (2012) CST Curation Set: 16146; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

14

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

15

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

16

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

17

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

18

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info